Constellium (CSTM) president awarded 10,210 restricted stock units in grant

Rhea-AI Filing Summary

Perkins Matthew B. reported acquisition or exercise transactions in this Form 4 filing.

CONSTELLIUM SE reported that executive Matthew B. Perkins, President, P&ARP, received an equity award in the form of 10,210 ordinary shares on March 12, 2026. The award was recorded at a price of $0.00 per share, indicating it is a compensation grant rather than an open-market purchase.

According to the footnote, this represents a grant of restricted stock units that vest in full on March 12, 2029, provided he remains employed through that date. Following this grant, Perkins directly holds 33,212 ordinary shares, reflecting his ongoing equity-based alignment with the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Perkins Matthew B.

Role President, P&ARP

Type	Security	Shares	Price	Value
Grant/Award	Ordinary shares	10,210	$0.00	--

Holdings After Transaction: Ordinary shares — 33,212 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Perkins Matthew B.

(Last) (First) (Middle)

300 EAST LOMBARD STREET

SUITE 1710

(Street)

BALTIMORE MD 21202

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CONSTELLIUM SE [ CSTM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, P&ARP

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary shares	03/12/2026	03/12/2026	A		10,210(1)	A	$0	33,212	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the grant of restricted stock units of Constellium SE, which vest in full on March 12, 2029, subject to the Reporting Person's continued employment.

Remarks:

	/s/ Kristine Carpenter, Attorney-in-Fact for Matthew Perkins	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CONSTELLIUM (CSTM) report for Matthew B. Perkins?

CONSTELLIUM reported that executive Matthew B. Perkins received a grant of 10,210 ordinary shares as an equity award. The grant was recorded at $0.00 per share, indicating compensation rather than a market purchase, and increases his directly held stake in the company.

Was the CONSTELLIUM (CSTM) Form 4 transaction a stock purchase or a grant?

The transaction was a grant, not a purchase. Matthew B. Perkins received 10,210 ordinary shares at $0.00 per share as a restricted stock unit award, reflecting equity-based compensation rather than an open-market buy or sell of CONSTELLIUM stock.

When do Matthew B. Perkins’ CONSTELLIUM (CSTM) restricted stock units vest?

The restricted stock units granted to Matthew B. Perkins vest in full on March 12, 2029. Vesting is conditioned on his continued employment with CONSTELLIUM SE through that date, aligning the award with long-term service and company performance.

How many CONSTELLIUM (CSTM) shares does Matthew B. Perkins hold after this Form 4?

After the reported grant, Matthew B. Perkins directly holds 33,212 CONSTELLIUM ordinary shares. This total includes the 10,210-share restricted stock unit award, reinforcing his equity exposure and linking a portion of his compensation to the company’s future performance.

What is the significance of the $0.00 price in the CONSTELLIUM (CSTM) Form 4 transaction?

The $0.00 per-share price indicates the shares were granted as compensation, not bought in the market. It reflects a restricted stock unit award to Matthew B. Perkins, rather than a cash-funded purchase or sale of CONSTELLIUM ordinary shares.